ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Venture capitalists invested $4.5 billion in biotechnology firms in 2013, an increase of 8% compared with 2012, according to a report from PricewaterhouseCoopers and the National Venture Capital Association. The number of investments made, however, dipped by 2% year-over-year. The biotechnology industry attracted the second-largest amount of funding after the software industry. Investor optimism was fueled by a strong exit market, an improved economy, and the involvement of corporations in deals, NVCA President Bobby Franklin says. In contrast, investments in the medical device industry fell 17% to $2.1 billion in 2013. The cleantech sector saw a precipitous 54% year-over-year drop in venture backing in 2013 to $1.5 billion. The high-water mark for cleantech venture backing was 2011, when the sector raised $4.4 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X